AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01908569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MACS
Description: The sperm will be subjected to capacitation through a density gradient together with the MACS technique in order to select the non-apoptotic spermatozoids.
Study NCT01908569 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NO MACS
Description: The sperm capacitation will be performed through a density gradient. The MACS technique will not be applied.
Study NCT00232908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV regimen
Description: As prescribed
Study NCT00232908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfuvirtide [Fuzeon]
Description: 90mg sc bid for 12 weeks
Study NCT02382016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Macitentan film-coated tablet 10 mg once daily.
Study NCT02382016 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet once daily.
Study NCT02412969 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Epidural
Description: control group will receive lumbar puncture epidural
Study NCT02412969 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dural Puncture Epidural
Description: intervention group will receive a dural puncture epidural
Study NCT04013191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil
Description: Padsevonil will be administered in predefined dosages.
Study NCT00943228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: High dose 4gms daily
Study NCT03292081 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OFDI
Description: PCI under OFDI guidance
Study NCT03292081 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IVUS
Description: PCI under IVUS guidance
Study NCT03961100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib 600 mg (T1)
Description: Test formulation 1 (T1): Multi-particulate formulation 1: entrectinib film-coated mini-tablets
Study NCT03961100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib 600 mg (T2)
Description: Test formulation 2 (T2): Multi-particulate formulation 2: entrectinib film-coated mini-tablets
Study NCT03961100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib 200 mg (R)
Description: Reference formulation (R): entrectinib hard capsules
Study NCT04374435 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MKTP with Surgical blade
Description: In this procedure, the donor skin will be harvested with a surgical blade and the donor skin will be dissociated
Study NCT04374435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MKTP with Negative Pressure Instrument
Description: In this procedure, the investigator uses a negative pressure instrument to create a few blisters on the donor skin and use the blisters for grafting after cell dissociation.
Study NCT03542825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Supplement
Description: Iron Sulphate 150 mg once daily
Study NCT03542825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chelates, Iron
Description: Amino acid chelated iron capsules contain 15 mg
Study NCT02442739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine 0.5 mg/kg mixed with syrup will be given by mouth once a week for 12 weeks.
Study NCT02442739 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo syrup will be given by mouth once a week for 12 weeks.
Study NCT01280643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00363272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ispinesib
Description: Given IV
Study NCT00363272 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00363272 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT03248557 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Spectral analysis of ventricular fibrillation tracings
Description: Up to 5-s long ventricular fibrillation segments will be extracted after segmentation and signal codification from artifact-free tracings. Signals will be band-pass filtered between 1.5 and 40 Hz. Averaged power spectral density will be obtained at each frequency using the non-parametric Welch method for using fast Fourier transform and normalized to the peak power in the 1.5-10 Hz band for each patient. Dominant frequency, HL-PSDR (the relative power between high and low frequency bands (cut-off: 3.9 Hz)) and HL-pKR ( relative number of spectral peaks above and below the 3.9 Hz threshold with power above 40% the frequency with the highest power), along with the number of DC shocks before ROSC, will be the variables used to obtain a model-derived risk score for outcome prediction.
Study NCT03808298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan therapeutic dose Treatment A
Description: Days 1-14: A single once daily dose at dose level A of balovaptan for 14 days
Study NCT04374435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suction blister grafting without cell dissociation
Description: In this procedure, an automated suction blister device will be used to create micro domes and these micro domes will be used directly for grafting without dissociation.
Study NCT04189224 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJV Investigational Multifocal Contact Lens
Description: TEST
Study NCT04189224 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-Day Acuvue® Moist Brand Multifocal Contact Lens
Description: CONTROL
Study NCT03800602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Given PO
Study NCT03800602 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT04220554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Improved support by health-care professionals
Description: Improved support to patients prescribed topical antipsoriatic drugs
Study NCT00566462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perampanel
Description: 2 mg/d for 14 days followed by 4 mg/d for 14 days
Study NCT00566462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo for for 14 days followed by 4 mg/d for 14 days
Study NCT03100591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-radiolabeled ACT-132577
Description: Single oral dose of 3.7 megabecquerel (MBq) (100 microcurie \[μCi\]) 14C-radiolabeled ACT-132577 administered as 1 capsule of 25 mg
Study NCT04881617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lexical Retrieval Training (LRT)
Description: In person or via teletherapy: Participants work on producing spoken and written names of personally relevant target items using a self-cueing hierarchy. Treatment focuses on the use of strategies that capitalize on spared cognitive-linguistic abilities to support word retrieval. The participant completes two (one hour each) sessions per week with a clinician plus daily home practice exercises.
Study NCT04881617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-Implemented Script Training for Aphasia (VISTA)
Description: In person or via teletherapy: Participants work on producing personally relevant scripts of 4-6 sentences in length. Length and complexity of scripts are individually tailored. The participant completes 30 minutes per day of home practice, during which they speak in unison with a video/audio model of a healthy speaker clearly articulating the scripts. Biweekly (one hour each) sessions with a clinician target clear and accurate script production, script memorization, and conversational usage of scripts.
Study NCT06304623 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived SVF IV administration
Description: Subjects received an intravenous injection of autologous adipose-derived SVF.
Study NCT01909089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spinal administration of chloroprocaine.
Description: In order to determine the minimum effective dose that is to be given spinally, an up-down sequential allocation will be used.~Efficacy of the analgesia will be evaluated by a 100mm visual analogue pain score (VAPS). There are two possible outcomes here:~* effective: the VAPS is 10mm or lower after the 15 minutes of monitoring. An effective result will decrease the test dose of chloroprocaine with 2mg for the next patient in this study.~* Ineffective: the VAPS is more than 10mm after 15 minutes of monitoring. An ineffective result will increase the test dose of chloroprocaine with 2mg for the next patient in this study. Patients who indicate an ineffective result will receive a rescue treatment by the administration of 12ml levobupivacaine epidurally.
Study NCT02644343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom Sound
Description: Custom Sound is the programming software used to program Nucleus cochlear implants.
Study NCT04355208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: (3M™ Filtek™ Universal )
Description: universal nanofillers resin composite (3M™ Filtek™ Universal )
Study NCT04355208 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: (3M™ Filtek™ Universal )
Description: universal nanofillers resin composite (3M™ Filtek™ Universal )
Study NCT03683017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoPulse 2.0
Description: Patients are given OrthoPulse 2.0, an extended OrthoPulse device with no zone control (ability for doctor to control treatment regions). Patients complete 10 minute treatments (5 minutes each arch) every day.
Study NCT00554814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bledilait Biofer®
Description: Bledilait Biofer® 2 mg/100 kcal
Study NCT00554814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milk supplemented with ferrous sulphate
Description: Milk supplemented with ferrous sulphate (2mg/100kcal)
Study NCT00554814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blédilait Biofer®
Description: Blédilait Biofer® milk (1,1mg/100kcal)
Study NCT02091102 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755nm Alexandrite Laser
Description: 755nm Alexandrite Laser for the treatment of Wrinkles
Study NCT01742832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vilazodone
Description: A fixed dose titration (with doses ranging from 10mg to 40mg/day) will be used. Subjects will take 10mg/day for 1 week, 20mg/day for 1 week and then 40mg/day.
Study NCT01742832 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Citalopram
Description: For those assigned to citalopram, the dose of citalopram will be maximized to 40mg/day. For those assigned to vilazodone, their citalopram dose will be maintained at 20mg/day for 1 week, then reduced to 10mg/day for 1 week, then switched to vilazodone 10mg/day.
Study NCT00617708 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cixutumumab
Description: Given IV
Study NCT00617708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO
Study NCT00617708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib hydrochloride
Description: Given PO
Study NCT00617708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00617708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT03808298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan supra-therapeutic dose Treatment B
Description: Days 1-14: A single once daily oral dose at dose level B of balovaptan for 14 days.
Study NCT03808298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active control [moxifloxacin] on Day 2 Treatment C
Description: Day 2: A single oral dose of 400 mg moxifloxacin capsule.
Study NCT03808298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active control [Moxifloxacin] on Day 15 Treatment D
Description: Day 15: A single oral dose of 400 mg moxifloxacin capsule.
Study NCT03808298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Balovaptan Treatment C
Description: Days 1-14: Matching placebo for balovaptan for 14 days.
Study NCT03808298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Balovaptan Treatment D
Description: Days 1-14: Matching placebo for balovaptan for 14 days.
Study NCT03808298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Moxifloxacin Treatment A
Description: Day 2 and 15: A single oral dose of a matching placebo capsule for moxifloxacin.
Study NCT01280643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT04258306 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Revifast
Description: Revifast® is based on natural resveratrol supported on Magnesium hydroxide. Revifast® particles confer an improved dissolution rate in tests that mimic the gastric environment compared to Polygonum cuspidatum resveratrol (98%).
Study NCT01280643 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: nucleic acid sequencing
Description: Correlative studies
Study NCT04258306 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: pure resveratrol
Description: resveratrol extracted from Polygonum cuspidatum resveratrol (98%).
Study NCT03930173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluciclovine
Description: A single dose of 18F-fluciclovine will be administered intravenously for PET/CT imaging. The standard 10 mCi dose will be used for this study.
Study NCT01280643 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Correlative studies
Study NCT03683017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoPulse 2.1
Description: Patients are given OrthoPulse 2.1, an extended OrthoPulse device with zone control (ability for doctor to control treatment regions). Patients complete 10 minute treatments (5 minutes each arch) every day.
Study NCT03683017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invisalign 3.5 Day Wear
Description: Patients are are fitted with sets of clear orthodontic Aligners by a qualified Principal Investigator (PI) using a ClinCheck plan by Align Technology. Aligners are worn for approximately 22 hours a day, and switched every 3.5 days.
Study NCT03683017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed Orthodontic Appliances (Braces)
Description: Patients are fitted with a set of brackets and wires, as per standard orthodontic treatment by a qualified Principal Investigator (PI).
Study NCT03237715 — intervention group
Intervention type: OTHER
Intervention: Assessment of unbound bilirubin levels
Description: Collection of residual blood for measurement of unbound bilirubin
Study NCT02238158 — intervention group
Intervention type: DRUG
Intervention: Atrovent® inhalets
Study NCT00571038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Led
Description: Post provided with blood pressure cuffs, pedometers and scale. Two post members trained as peer leaders who encourage post members to take positive steps to improve BP. Peer leader training involves 20 hours of training over 12 months, telephone/email access to clinical experts and educational materials to share with post members.
Study NCT03930173 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT of the brain
Description: Each subject will undergo 18F-fluciclovine PET/CT of the brain which will be performed ≤ 30 days from equivocal MRI brain
Study NCT00021099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV
Study NCT00571038 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Seminar
Description: Post provided with blood pressure cuffs, pedometers and scale. Post members, including study participants invited to didactic sessions on cardiovascular health.
Study NCT02551822 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sacral neuromodulator
Description: The Implanted Pulse Generator will be set via randomization to continuous vs cycling stimulation.
Study NCT05887050 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active
Description: Blend of chromium, amla fruit extract, and citrus bioflavonoids
Study NCT05887050 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin tablet
Study NCT01908478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Study NCT01908478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT01908478 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy
Study NCT02675608 — intervention group
Intervention type: BIOLOGICAL
Intervention: Influenza Virus Vaccine
Description: On the first visit, subjects are vaccinated with the 2015-2016 seasonal flu vaccine.
Study NCT04138446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altitude exposure in climate chamber
Description: Altitude exposure in a climate chamber will consist of hypobaric hypoxia similar to the conditions found at 3000m asl and 5000m asl.
Study NCT04138446 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Altitude exposure in climate chamber
Description: Altitude exposure in a climate chamber will consist of hypobaric hypoxia similar to the conditions found at 3000m asl and 5000m asl.
Study NCT02057172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM11260C
Description: HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
Study NCT03868202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Transdermal Product
Description: Hormone replacement therapy will be given to postmenopausal women for up to 1 month.
Study NCT02057172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Liraglutide is a GLP-1 agonist.
Study NCT02057172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03954821 — intervention group
Intervention type: DEVICE
Intervention: prefabricated insoles
Study NCT02889211 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gambling Task
Study NCT03961100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib 200 mg (T)
Description: Test formulation (T): entrectinib HPMC capsules
Study NCT02990169 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CATS tonometer prism
Description: IOP tonometer prism for assessment of intraocular pressure
Study NCT02990169 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Goldmann Tonometer prism
Description: IOP tonometer prism for assessment of intraocular pressure
Study NCT04147312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fufang E'Jiao Jiang
Description: Fufang E'Jiao Jiang, 20milliliters(mL) once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles
Study NCT04147312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo containing low-dose fufang E'Jiao Jiang
Description: placebo containing low-dose Fufang E'Jiao Jiang, 20mL once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles
Study NCT02340299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nHFOV
Description: Extubation to ventilator-derived nHFOV using binasal prongs
Study NCT02340299 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nCPAP
Description: Extubation to ventilator-derived nCPAP using binasal prongs
Study NCT03645668 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Meropenem Injection
Description: Different administration types between two groups
Study NCT03645668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem Injection
Description: Different administration types between two groups
Study NCT01659112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stabilization
Description: A 6-week (3 days a week) exercise intervention including progressive core exercises was performed.
Study NCT01659112 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional upper extremity rehabilitation
Description: A 6-week (3 days a week) exercise intervention of the injured joint based on the recovery process was performed.
Study NCT01659112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional upper extremity rehabilitation
Description: A 6-week (3 days a week) exercise intervention of the injured joint based on the recovery process was performed.
Study NCT01339351 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Group by Teleconference
Description: 10 sessions